Table 1. Patient demographics and baseline characteristics.
| Parameters | Switched aflibercept (n=107) | Naïve aflibercept (n=58) | P |
| Age (a, range) | 80.0±7.4 (62-96) | 82.8±7.4 (60-96) | 0.01a |
| Sex (n, %) | 0.07 | ||
| F | 60 (56) | 41 (70) | |
| M | 47 (44) | 17 (30) | |
| CNV subtypes (n, %) | |||
| PC | 7 (7) | 4 (7) | 1.0 |
| MC | 3 (3) | 6 (10) | 0.07 |
| Occult | 44 (41) | 31 (53) | 0.14 |
| FVPED | 51 (48) | 17 (29) | 0.03a |
| PPCNV | 2 (2) | 0 (0) | 0.54 |
| BCVA at study entry point (ETDRS letters, 95% CI) | 56.3±14.8 (53.5-59.1) | 54.1±13.0 (50.6-57.5) | 0.33 |
| Baseline CRT at entry point (µm, 95% CI) | 254.4±34.5 (247.8-261.0) | 284.2±55.1 (269.7-298.7) | <0.0001a |
| Follow-up (mo) | 12 | 12 | - |
| Mean No. of injections | 7.5±0.9 | 7.1±0.8 | 0.003a |
aSignificant, 14 of the 107 eyes had received a combination of ranibizumab and bevacizumab therapy. PC: Predominantly classic; MC: Minimally classic; FVPED: Fibrovascular pigment epithelial detachment; PPCNV: Peri-papillary choroidal neovascular membrane; SD: Standard deviation; CI: Confidence interval; ETDRS: Early Treatment Diabetic Retinopathy Study.
x±s